Armed interference: Oncolytic viruses engineered to carry antitumor shRNAs

Molecular Therapy

Volumn 15, Issue 2, 2007, Pages 227-228

  Kirn, David ^a  

^a Jennerex Biotherapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BEVACIZUMAB; BIOVEX; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; JX 594; ONCOLYTIC VIRUS; ONCOVEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; CANCER RESISTANCE; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HUMAN; MEASLES VIRUS; NONHUMAN; NOTE; ONCOLYTIC VIROTHERAPY; PROTEIN SYNTHESIS INHIBITION; RNA INTERFERENCE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846293658     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300089     Document Type: Note

References (12)

1. Kirn, D, Martuza, RL and Zwiebel, J (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 7: 781-787.
2. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
3. Todo, T, Rabkin, SD, Sundaresan, P, Wu, A, Meehan, KR, Herscowitz, HB et al. (1999) Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 10: 2741-2755.
4. Wang, Y, Hallden, G, Hill, R, Brooks, G, Francis, J and Kirn, D. (2003). E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21: 1328-1335.
5. Khuri, F, Nemunaitis, J, Ganly, I, Gore, M, MacDougal, M, Tannock, I et al. (2000). A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
6. Hermiston, T (2002). Fighting fire with fire: Attacking the complexity of human tumors with armed therapeutic viruses. Curr Opin Mol Ther 4: 334-342.
7. Kim, JH, Oh, JY, Park, BH, Lee, DE, Kim, JS, Park, HE et al. (2006). Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14: 361-370.
8. Liu, BL, Robinson, M, Han, ZQ, Branston, RH, English, C, Reay, P et al. (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10: 292-303.
9. Hasegawa, K, Pham, L, O'Connor, MK, Federspiel, MJ, Russell, SJ and Peng, KW (2006). Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 12: 1868-1875.
10. Thorne, SH, Tam, BY, Kirn, DH, Contag, CH, and Kuo, CJ (2006). Selective intratumoral amplification of an anti-angiogenic vector by an oncolytic virus produces enhanced antivascular and antitumor efficacy. Mol Ther 13: 938-946.
11. Yoo, JY, Kim, J-H, Kwon, Y-G, Kim, E-C, Kim, NK, Choi, HJ and Yun, C-O (2007). VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 15: 295-302.
12. Behlke, MA (2006). Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670.